Debiopharm signs licensing agreement for sexual deviations drug

Salvacyl, a gonadotropin releasing hormone agonist analogue, is said to be effective in the treatment of severe sexual deviations in adult men by inducing and maintaining a reversible reduction of testosterone to castrate serum levels.

Debiopharm has developed and received marketing authorizations for Salvacyl / Moapar in nine major European countries, including France, Germany, UK, Sweden, Norway, Denmark, Belgium, the Netherlands and Finland.

Rolland-Yves Mauvernay, president and founder of Debiopharm, said: “There is a genuine unmet medical and social need for the treatment of sexual deviations. Not many pharma companies are willing or courageous enough to provide this type of treatment but we feel that we have a responsibility to help doctors and patients with the tools they need, even if it is difficult or controversial.”